HER2-targeting Peptide Drug Conjugate with Better Penetrability for Effective Breast Cancer Therapy
Antibody-drug conjugates (ADCs) have the following advantages: target specificity; wide therapeutic index; and prolonged circulation half-life. A key limitation of ADCs, however, is the large size (~150 kDa), which markedly slows diffusion through the interstitium of solid tumors and prevents effici...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Compuscript Ltd
2023-12-01
|
| Series: | BIO Integration |
| Subjects: | |
| Online Access: | https://www.ingentaconnect.com/contentone/cscript/bioi/2023/00000004/00000004/art00004 |